Evidence map›Paper›PMID 37736959›Full record

ArticleMethods and protocols2023

Health Benefits of Montmorency Tart Cherry Juice Supplementation in Adults with Mild to Moderate Ulcerative Colitis: A Protocol for a Placebo Randomized Controlled Trial.

Jonathan Sinclair, Stephanie Dillon, Robert Allan, Johanne Brooks-Warburton, Terun Desai, Charlotte Lawson, Lindsay Bottoms

Registry-linked trialOpen access · goldAbstract read
In one paragraph

Article in Methods and protocols, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05486507 (The Health Benefits of Montmorency Tart Cherry Juice Supplementation in Adults With Mild to Moderate Ulcerative Colitis; a Placebo Randomized Control Trial), which is not on this map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.9field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05486507 nacompletednot on this map

The Health Benefits of Montmorency Tart Cherry Juice Supplementation in Adults With Mild to Moderate Ulcerative Colitis; a Placebo Randomized Control Trial

TypeinterventionalSponsorUniversity of Central LancashireRan2023 to 2024Enrolled40ConditionsUlcerative ColitisArmsMontmorency tart cherry, Placebo
3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Jonathan SinclairResearch Centre for Applied Sport, Physical Activity and Performance, School of Sport & Health Sciences, Faculty of Allied Health and Wellbeing, University of Central Lancashire, Preston PR1 2HE, UK.ORCID 0000-0002-2231-3732
Stephanie DillonResearch Centre for Applied Sport, Physical Activity and Performance, School of Sport & Health Sciences, Faculty of Allied Health and Wellbeing, University of Central Lancashire, Preston PR1 2HE, UK.ORCID 0000-0002-3369-8199
Robert AllanResearch Centre for Applied Sport, Physical Activity and Performance, School of Sport & Health Sciences, Faculty of Allied Health and Wellbeing, University of Central Lancashire, Preston PR1 2HE, UK.ORCID 0000-0002-9021-8737
Johanne Brooks-WarburtonGastroenterology Department, Lister Hospital, Stevenage SG1 4AB, UK.
Terun DesaiSchool of Life and Medical Sciences, University of Hertfordshire, Hatfield, AL10 9AB, UK.ORCID 0000-0001-8606-0458
Charlotte LawsonDepartment of Comparative Biomedical Sciences, Royal Veterinary College, London NW1 0TU, UK.
Lindsay BottomsSchool of Life and Medical Sciences, University of Hertfordshire, Hatfield, AL10 9AB, UK.ORCID 0000-0003-4632-3764
University of Hertfordshire · GBUniversity of Lancashire · GBRoyal Veterinary College · GB

Funding

Cherry Marketing Institute N/A
6 · The paper itself

Abstract

Ulcerative colitis, characterized by its relapsing and remissive nature, negatively affects perception, body image, and overall quality of life. The associated financial burden underscores the need for alternative treatment approaches with fewer side effects, alongside pharmaceutical interventions. Montmorency tart cherries, rich in anthocyanins, have emerged as a potential natural anti-inflammatory agent for ulcerative colitis. This manuscript outlines the study protocol for a randomized placebo-controlled trial investigating the effects of Montmorency tart cherry in individuals with ulcerative colitis. The trial aims to recruit 40 participants with mild to moderate disease activity randomly assign them to either a Montmorency tart cherry or placebo group. The intervention will span 6 weeks, with baseline and 6-week assessments. The primary outcome measure is the Inflammatory Bowel Disease Quality of Life Questionnaire. Secondary outcomes include other health-related questionnaires and biological indices. Statistical analysis will adhere to an intention-to-treat approach using linear mixed effect models. Ethical approval has been obtained from the University of Hertfordshire (cLMS/SF/UH/05240), and the trial has been registered as a clinical trial (NCT05486507). The trial findings will be disseminated through a peer-reviewed publication in a scientific journal.

Indexed as

complimentary medicineinflammatory bowel diseaseMontmorency tart cherryrandomized controlled trialulcerative colitis

Identifiers

PMID37736959
PMCPMC10514793
OpenAlexW4386219554

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.